Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
To determine the effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme.
Randomized, double-blind, parallel group design.
The primary outcome was all-cause death. The outcomes in the three component trials were: cardiovascular death or hospitalization for worsening heart failure; cardiovascular death, admission to hospital for CHF, or non-fatal myocardial infarction; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, or non-fatal stroke; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation; death (any cause) or admission to hospital for CHF; and development of new diabetes. All outcome events were adjudicated.